Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-11-04 Report Publication Anno…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Pl. find attached newspaper publication of results for the quarter and half year ended 30th September 2023.
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India and BSE Limited, dated 4th November 2023. It announces the publication of the company's unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2023, which were approved by the Board of Directors on 2nd November 2023. The letter states that the financial results have been published in newspapers and are available on the company's website. The document is essentially a notification about the publication of financial results rather than the financial results report itself. It does not contain detailed financial statements or substantive financial data but rather informs about the advertisement and availability of the results. According to the "Menu vs Meal" rule, such a document is classified as a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2023-11-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 03.11.2023 from Morepen Laboratories Limited addressed to stock exchanges. It informs about the availability of the audio recording of the Earnings Conference Call held on the same date regarding unaudited financial results for the quarter and half year ended September 30, 2023. The document does not contain the transcript or detailed financial data but only provides a link to the audio recording. Given the short length (1819 characters) and the nature of the content (announcement of availability of earnings call audio), this fits the category of a Call Transcript (CT) announcement rather than the transcript itself. However, since it is only announcing the audio recording and not providing the transcript text, it is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure under SEBI Listing Regulations and does not contain the full transcript or financial data itself. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-11-03 English
Audio recording of earning conference call held on 3rd November 2023.
Call Transcript Classification · 95% confidence The document is a short announcement dated November 3, 2023, from Morepen Laboratories Limited addressed to stock exchanges. It informs about the availability of the audio recording of the Earnings Conference Call held on the same day regarding unaudited financial results for the quarter and half year ended September 30, 2023. The document does not contain the transcript or detailed financial data but only provides a link to the audio recording. According to the rules, announcements about availability of conference call recordings or transcripts are classified as Call Transcript (CT) if the full transcript is provided. However, this document only announces the audio recording availability and does not contain the transcript itself. Given the short length (1819 characters) and the nature of the content, it is an announcement related to the earnings call audio recording, which aligns best with Call Transcript (CT) category as it relates directly to the earnings call content. The confidence is high because the document explicitly states it is about the earnings conference call audio recording and references the quarter and half year financial results period.
2023-11-03 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation (Q2’ FY24) November 2023' and is addressed to stock exchanges with the subject clearly indicating it is an earnings presentation for the quarter and half year ended 30th September 2023. The content includes detailed financial performance data, quarterly and half-yearly highlights, segment-wise performance, revenue growth, and business updates. The document length is about 15,000 characters, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full quarterly report with financial statements, but rather a presentation summarizing earnings and business highlights for investors and stakeholders. Therefore, the document fits the category of an Investor Presentation (IP) rather than an Earnings Release (ER) or Interim Report (IR).
2023-11-02 English
Please find attached (Q2-FY24) presentation.
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation (Q2’ FY24) November 2023' and contains detailed financial performance data for the quarter and half year ended 30th September 2023. It includes revenue, profit, segment-wise performance, and growth analysis. The document is about 15,000 characters long and is a presentation format, not a full financial report or regulatory filing. It is clearly an investor-focused presentation summarizing quarterly financial results and business highlights. Therefore, it fits the category of an Investor Presentation (IP).
2023-11-02 English
Please find attached financial results for the quarter and half year ended on September 30, 2023 along-with limited review report thereon.
Regulatory Filings
2023-11-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.